HM Ciocc Leads Private Oncology Research in Madrid with 144 Clinical Trials Open in 2024

The Clara Campal Comprehensive Oncology Centre ( HM Ciocc ), located at the HM Sanchinarro University Hospital, has been highlighted in the Radiography report on the state of cancer research in the Community of Madrid 2024, prepared by the Spanish Association Against Cancer ( AECC ). With 144 clinical trials open for recruitment and a total of 374 active studies during the year.

In this way, HM Ciocc leads oncological research among private hospitals in Madrid and occupies the second overall position in the region, only behind the Hospital Universitario 12 de Octubre. “ We work daily so that patients who come to our center can have access to the latest therapeutic developments . This expands the range of options and improves their prognosis ,” says Dr. Antonio Cubillo , director of HM Ciocc.

Immunotherapy and advanced therapies were the protagonists of the trials carried out during 2024. According to Dr. César Muñoz, clinical scientific coordinator of the HM Hospitales Research Foundation, having clinical trials expands the available therapeutic options that can change the course of the disease. Immunotherapy and advanced therapies have revolutionized cancer treatment, providing alternatives that were previously unthinkable.

Immunotherapy and advanced therapies are the focus of many clinical trials, with early phases standing out, and digestive and breast cancer are the areas with the most research.

Scientific publications and research by HM Ciocc

Throughout the year, HM Ciocc accumulated more than 100 scientific publications, highlighting two studies published in Nature Medicine . One of them, led by Dr. Emiliano Calvo, director of the HM Ciocc Start Early Phases Unit, explored the OMO-103 mutation in solid tumors. The other, led by Dr. Jesús García Donas, head of the Gynecological and Genitourinary Tumors Unit, investigated a targeted therapy in urothelial and bladder cancer. Regarding the areas investigated, digestive and breast tumors led the research, with a predominance of early-phase trials.

HM Ciocc’s comprehensive strategy combines cutting-edge technology, multidisciplinary teams and a national and international collaboration network, consolidating it as a benchmark in oncology research in Spain.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us